<DOC>
	<DOCNO>NCT00371774</DOCNO>
	<brief_summary>Purpose : To develop real time national clinical database support share best practice , 1 . To generate hypothesis future clinical research 2 . To understand AMEVIVE use routine clinical practice/real world set . Each patient visit include follow observational endpoint : 1 . AMEVIVE dose 2 . Number course 3 . Concomitant treatment 4 . Response treatment ( patient physician global assessment ) 5 . Status psoriasis-related medical condition 6 . Time re-treatment .</brief_summary>
	<brief_title>Amevive Wisdom Acquired From Real-Time Evidence ( A.W.A.R.E™ ) Program</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Amevive clinically indicate patient Amevive contraindicate patient</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Amevive®</keyword>
	<keyword>alefacept</keyword>
</DOC>